2475-80-1

Usage

Uses

Used in Organic Synthesis:
METHYL 2-AMINO-5-METHOXYBENZOATE is used as a key intermediate in organic synthesis for the production of various chemical compounds. Its presence in the synthesis process allows for the creation of a wide range of products with diverse applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, METHYL 2-AMINO-5-METHOXYBENZOATE is utilized as a vital raw material for the development of new drugs and medications. Its unique properties contribute to the formulation of innovative pharmaceutical products that address various health concerns.
Used in Agrochemicals:
METHYL 2-AMINO-5-METHOXYBENZOATE plays a significant role in the agrochemical industry, where it is employed as a raw material for the production of various agrochemical products. Its use in this sector helps in the development of effective solutions for agricultural applications.
Used in Dye Industry:
In the dye industry, METHYL 2-AMINO-5-METHOXYBENZOATE is used as an essential intermediate for the synthesis of different types of dyes. Its contribution to the dye manufacturing process results in the creation of a diverse range of dyes for various applications.

InChI:InChI=1/C9H11NO3/c1-12-6-3-4-8(10)7(5-6)9(11)13-2/h3-5H,10H2,1-2H3

Upstream product

• 394-31-0 2-amino-5-hydroxybenzoic acid 
• 1882-72-0 methyl 2-amino-5-hydroxybenzoate 
• 77-78-1 dimethyl sulfate 
• 2327-45-9 methyl 2-nitro-5-(methoxy)benzoate 
• 77-76-9 2,2-dimethoxy-propane 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 
• 74-87-3 methylene chloride 
• 1882-69-5 5-methoxy-2-nitro-benzoic acid 
• 186581-53-3 diazomethane 
• 2516-95-2 5-chloro-2-nitrobenzoic acid 
• 610-37-7 5-hydroxy-2-nitrobenzoic acid 
• 59216-77-2 methyl 5-hydroxy-2-nitro-benzoate 
• 67-56-1 methanol 
• 39755-95-8 5-methoxyisatine 

Downstream Products

• 54166-82-4 2'-Carboxy-4'-methoxyoxanilic acid 1-ethyl 2'-methyl ester 
• 39495-36-8 methyl 2-acetylamino-5-methoxybenzoate 
• 675578-40-2 N-p-toluenesulfonyl-5-methoxyanthranilic acid methyl ester 
• 19181-64-7 6-methoxyquinazolin-4-ol 
• 906648-99-5 3-(2-amino-5-methoxy-phenyl)-pentan-3-ol 
• 89433-06-7 2-(2-amino-5-methoxyphenyl)propan-2-ol 
• 1171107-23-5 methyl 5-methoxy-2-(1H-pyrrol-1-yl)benzoate 
• 344333-11-5 methyl 2-isothiocyanato-5-methoxybenzoate 
• 1448676-73-0 2-cyclobutyl-7-methoxy-4-(4-(2-methoxyphenyl)piperazin-1-yl)quinazoline 
• 1357830-08-0 6-methoxy-3-phenylquinazolin-4(3H)-one 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors

An interesting enzyme of the endocannabinoid system is monoacylglycerol lipase (MAGL). This enzyme, which metabolizes the endocannabinoid 2-arachidonoylglycerol (2-AG), has attracted great interest due to its involvement in several physiological and pathological processes, such as cancer progression. Experimental evidences highlighted some drawbacks associated with the use of irreversible MAGL inhibitors in vivo, therefore the research field concerning reversible inhibitors is rapidly growing. In the present manuscript, the class of benzoylpiperidine-based MAGL inhibitors was further expanded and optimized. Enzymatic assays identified some compounds in the low nanomolar range and steered molecular dynamics simulations predicted the dissociation itinerary of one of the best compounds from the enzyme, confirming the observed structure-activity relationship. Biological evaluation, including assays in intact U937 cells and competitive activity-based protein profiling experiments in mouse brain membranes, confirmed the selectivity of the selected compounds for MAGL versus other components of the endocannabinoid system. An antiproliferative ability in a panel of cancer cell lines highlighted their potential as potential anticancer agents. Future studies on the potential use of these compounds in the clinical setting are also supported by the inhibition of cell growth observed both in cancer organoids derived from high grade serous ovarian cancer patients and in pancreatic ductal adenocarcinoma primary cells, which showed genetic and histological features very similar to the primary tumors.

Oxidative ring-opening of isatins for the synthesis of 2-aminobenzamides and 2-aminobenzoates

An efficient and practical isatin-based oxidative domino protocol has been developed for the facile synthesis of 2-aminobenzamides and 2-aminobenzoates. The robust nature of this reaction system is reflected by accessible starting materials, room temperature and high-yield gram-scale synthesis.

BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

Preparation technology of 6-hydroxy-bentazone

The invention discloses a preparation technology of 6-hydroxy-3-isopropyl-1H-benzo[c][1,2,6]thiadiazine-4(3H)-keto-2,2-dioxide. The preparation technology includes subjecting 5-chloro-2-nitrobenzoic acid serving as a raw material to hydrolysis reaction an

Distinct urinary metabolite profiles of two pharmacologically active N-methylanthranilates: Three approaches to xenobiotic metabolite identification

Two volatile alkaloids, isopropyl N-methylanthranilate (IMA) and methyl N-methylanthranilate (MMA), present in the human diet and cosmetic products, were recently demonstrated to possess important pharmacological activities. While MMA is considered to be phototoxic, there is scarce data on the toxicity of IMA. Herein, we analyzed urinary metabolites of IMA and MMA in rats (200 mg kg?1, i.p., 7 days) by combining three different approaches: 1) preparative chromatography, 2) synthesis, and 3) SPR. The preparative approach, Sephadex LH-20 chromatography of the extract of urine samples of IMA treated animals, in conjunction with NMR, enabled the identification of 16 different anthranilate derivatives, among which products of aromatic core hydroxylation (isopropyl 5-hydroxy-N-methylanthranilate, isopropyl 5-hydroxyantranilate, isopropyl 3-hydroxyantranilate) were the major ones. The first application of the synthetic/combinatorial approach led to a successful identification of MMA metabolites, where 2-(methylamino)benzamide and N-methylanthranilic acid were the principal ones, among 14 others. Generally, MMA and IMA undergo analogous biotransformation pathways; however, MMA predominantly underwent chemical conversions of the ester group, i.e. transformation into derivatives of anthranilamide and anthranilic acid, while the major metabolic pathway of IMA was hydroxylation of the aromatic core. Additionally, pathohistological examinations revealed no signs of liver toxicity, or other signs of toxicity.

Concise Synthesis of Dictyoquinazol A via a Dimerisation-Cyclocondensation Sequence

A two-step total synthesis of the neuroprotective alkaloid, dictyoquinazol A, has been achieved. The brevity of this synthesis was enabled by exploiting the hidden symmetry of the target molecule. Several structural analogues were also prepared using a similar strategy. These results provide a platform for future structure-activity relationship studies in the quest for a novel treatment for stroke.

SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF

Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.

NEW ANTIVIRAL COMPOUNDS

The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.

Discovery of novel Tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats

Tricyclic analogues were rationally designed as the high affinity niacin receptor G-protein-coupled receptor 109A (GPR109A) agonists by overlapping three lead structures. Various tricyclic anthranilide and cycloalkene carboxylic acid full agonists were di

AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR

The present invention provides a compound represented by the following formula (I): [wherein, A represents a group of the following formula (A-1): etc., R1 and R2 each independently represent a hydrogen atom etc., Z represents CR3 etc., W represents CR4 etc., Q represents CR5 etc., R3, R4 and R5 each independently represent a hydrogen atom etc., Y represents an oxygen atom or sulfur atom, X represents an oxygen atom etc. and B represents an optionally substituted aryl group or optionally substituted heteroaryl group], the prodrug thereof or the pharmaceutically acceptable salt thereof for preventing or treating various diseases such as hypertesion, cerebral stroke, cardiac failure, etc.